

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Gaush Meditech Ltd

高视医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2407)

VOLUNTARY ANNOUNCEMENT INTENTION TO CONDUCT ON-MARKET SHARE REPURCHASE

This announcement is made by Gaush Meditech Ltd (the “**Company**”) on a voluntary basis.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company wishes to announce that on June 12, 2024, the Board resolved to repurchase shares of the Company (the “**Shares**”) in the open market from time to time at a maximum aggregate amount of HK\$50 million in value for a period commencing from June 13, 2024 and until the conclusion of the next annual general meeting of the Company (the “**Proposed Share Repurchase**”), pursuant to the share repurchase mandate granted to the Directors to repurchase Shares not exceeding 10% of the total number of issued Shares as at May 30, 2024 (i.e. 14,797,036 Shares) as approved by the shareholders of the Company (the “**Shareholders**”) at the annual general meeting held on May 30, 2024 (the “**Share Repurchase Mandate**”).

The Proposed Share Repurchase will be funded by the Company’s internal resources. The Company will conduct the Proposed Share Repurchase in compliance with the sixth amended and restated memorandum and articles of association of the Company, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”), the Codes on Takeovers and Mergers and Share Buy-backs issued by the Securities and Futures Commission of Hong Kong (the “**Takeovers Code**”), the Companies Act (as revised) of the Cayman Islands and all applicable laws and regulations to which the Company is subject.

The Proposed Share Repurchase will not result in the number of Shares held by the public falling below the minimum percentage as required under the Listing Rules. The Board has no intention to exercise the Share Repurchase Mandate to the extent that would give rise to an obligation to make a general offer to the Shareholders under the Takeovers Code.

The Company believes that the Proposed Share Repurchase can demonstrate the Company's confidence in its own business outlook and prospects and would, ultimately, benefit the Company and create value to its Shareholders. The Board believes that the current financial resources of the Company would enable it to implement the Proposed Share Repurchase while maintaining a solid financial position.

Shareholders and potential investors should note that the implementation of the Proposed Share Repurchase by the Company will be subject to market conditions and will be at the absolute discretion of the Board and/or its authorized person(s). There is no assurance of the timing, quantity or price of any repurchases of Shares or whether the Company will make any repurchases of Shares at all. Shareholders and potential investors are advised to exercise caution when dealing in the Shares.

By order of the Board
Gaush Meditech Ltd
Mr. Gao Tieta
Chairman and Executive Director

Hong Kong, June 12, 2024

As of the date of this announcement, the Board comprises Mr. Gao Tieta as Chairman and executive Director, Mr. Liu Xinwei, Mr. Zhao Xinli, Mr. Zhang Jianjun and Ms. Li Wenqi as executive Directors, Dr. David Guowei Wang as non-executive Director, and Mr. Feng Xin, Mr. Wang Li-Shin and Mr. Chan Fan Shing as independent non-executive Directors.